Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalated Daunorubicin and Cytarabine in Older AML
NCT02432872Unknown
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of daunorubicin and cytarabine in acute myeloid leukemia (AML) (4 arms). Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
daunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02432872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432872.